Expert Interview
A Second Opinion: Interpreting both Alkermes’ ALKS-2680 and Takeda’s TAK-861 initial data for narcolepsy and how the OX2R class may ultimately fit in the treatment paradigm
Ticker(s): ALKS, TAK, CNTAInstitution: Montefiore Medical Center
- Professor of Clinical Neurology at Albert Einstein College of Medicine, Director of the Sleep-Wake Disorders Center at Montefiore Medical Center & President of the New York State Society of Sleep Medicine.
- Currently manages 10 patients a week with insomnia.
- Research focuses on narcolepsy, insomnia and sleep apnea; chaired the first International Classification of Sleep Disorders and has published more than 200 peer-reviewed articles and chapters.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
